Skip to main content


Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

Fig. 1

RA-BEYOND vaccine substudy design. Primary assessment was satisfactory humoral response to PCV-13 and TTV. *Background conventional synthetic disease-modifying antirheumatic drugs allowed except cyclosporine, azathioprine or leflunomide. MTX = methotrexate; PCV-13 = 13-serotype pneumococcal conjugate vaccine; TTV = tetanus toxoid vaccine

Back to article page